Factor Xa acts as a PDGF-independent mitogen in human vascular smooth muscle cells

Thrombosis and Haemostasis

Volumn 84, Issue 3, 2000, Pages 499-505

  Bretschneider, E ^a   Braun, M ^a   Fischer, A ^a   Wittpoth, M ^a   Glusa, E ^a   Schror, K ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Factor Xa; Mitogenesis; Thrombin generation; Vascular smooth muscle cells

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; 2,7 [4 AMIDINOBIS(BENZYLIDENE)] 1 CYCLOHEPTANONE; BENZYLIDENE DERIVATIVE; BLOOD CLOTTING FACTOR 10A; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; THROMBIN; THYMIDINE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG INHIBITION; DRUG POTENTIATION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERPLASIA; MITOGENICITY; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; SAPHENOUS VEIN; SIGNAL PROCESSING; SMOOTH MUSCLE FIBER; THROMBOSIS;

EID: 0033832497     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614051     Document Type: Article

References (32)

1. Pathologic changes in coronary artery saphenous vein grafts and related etiologic factors
2. Coronary bypass graft fate and patient outcome: Angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years
3. Stranger in a strange land: The pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries
4. Aortocoronary saphenous vein graft disease. Pathogenesis, predisposition, and prevention
5. Nature and pressure dependence of damage induced by distension of human saphenous vein coronary artery bypass grafts
6. Improved preservation of saphenous vein grafts by the use of glyceryl trinitrate-verapamil solution during harvesting
7. Molecules in focus. Tissue factor
8. Agonist-mediated tissue factor expression in cultured vascular smooth muscle cells
9. Localization and activity of tissue factor in human aortic atherosclerotic lesions
10. Exp Opin Invest Drugs
11. Cytokinetic study of aortocoronary bypass vein grafts in place for less than six months
12. Activation of NFκB is essential but not sufficient to stimulate mitogenesis of vascular smooth muscle cells
13. Different effects of thrombin receptor activation on endothelium and smooth muscle cells of human coronary bypass vessels
14. Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells
15. Coagulation factor Xa stimulates platelet-derived growth factor release and mitogenesis in cultured vascular smooth muscle cells of rat
16. Effector cell protease receptor-1 is a vascular receptor for coagulation factor Xa
17. Effector protease receptor 1 mediates the mitogenic activity of factor Xa for vascular smooth muscle cells in vitro and in vivo
18. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
19. Synthetic inhibitors of bovine factor Xa and thrombin. Comparison of their anticoagulant efficiency
20. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa
21. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model
22. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs
23. Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway
24. Neointimal thickening after severe coronary artery injury is limited by short-term administration of a factor Xa inhibitor
25. Relation of coronary angioscopic findings at coronary angioplasty to angiographic restenosis
26. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors
27. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots
28. The molecular basis of blood coagulation
29. Xa receptor EPR-1
30. Activation of endothelial cells by factor Xa reveals a new mode of activation of the PAR-2 receptor
31. Coagulation factors VIIa and Xa induce cell signaling leading to up-regulation of the egr-1 gene
32. Differential expression of functional protease-activated receptor-2 (PAR-2) in human vascular smooth muscle cells